With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Industry groups have lined up on opposite sides of Illinois legislation aimed at providing patient access to discount ...